MORPHIMMUNE, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • August 8th, 2023 • Immunome Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of __________, and is between Morphimmune Inc., a Delaware corporation (together with its subsidiaries, the “Company”), and __________ (“Indemnitee”).
MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • August 8th, 2023 • Immunome Inc. • Pharmaceutical preparations • Indiana
This Master Sponsored Research Agreement (“Agreement”), made as of February 1, 2022 (“Effective Date”), by and among MorphImmune, Inc (“COMPANY” or “Sponsor” or “Company”), a corporation having its principal place of business at 1281 Win Hentschel Blvd. Suite 1300, West Lafayette, IN 47906; Purdue Research Foundation (“PRF”) 1281 Win Hentschel Blvd., West Lafayette, Indiana 47906; and Purdue University (“Purdue” or “University”), 610 Purdue Mall, West Lafayette, Indiana 47907-2040, (each a “Party” and collectively, the “Parties”).
MASTER LICENSE AGREEMENTMaster License Agreement • August 8th, 2023 • Immunome Inc. • Pharmaceutical preparations • Indiana
THIS MASTER LICENSE AGREEMENT is made and entered into as of January 19th, 2022 (“Effective Date”), by and between PURDUE RESEARCH FOUNDATION, a statutory body corporate formed and existing under the Indiana Foundation or Holding Companies Act of 1921 (“PRF”) with its main offices located at 1281 Win Hentschel Blvd, West Lafayette, IN 47906, and MorphImmune, Inc., a Delaware corporation with its principal place of business located at 1281 Win Hentschel Blvd., West Lafayette, IN 47906 (“LICENSEE”) (each hereinafter referred to individually as a “Party” and collectively as the “Parties”).
MORPHIMMUNE INC.2020 Equity Incentive Plan • August 8th, 2023 • Immunome Inc. • Pharmaceutical preparations • Delaware
Unless otherwise defined herein, the terms defined in the 2020 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
